// App-Quantinova.ai

552 : Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Researchers

Presenter

  • Raymond L. Comenzo

Principal Investigators

  • Giovanni Palladini

  • Monique C. Minnema

  • Ashutosh D. Wechalekar

  • Arnaud Jaccard

  • Vaishali Sanchorawala

  • Hans C. Lee

  • Simon D. Gibbs

  • Peter Mollee

  • Christopher P. Venner

  • Jin Lu

  • Stefan Schnland

  • Moshe Gatt

  • Kenshi Suzuki

  • Kihyun Kim

  • M. Teresa Cibeira

  • Meral Beksac

  • Edward Libby

  • Jason Valent

  • Vania T. M. Hungria

  • Sandy W. Wong

  • Michael Rosenzweig

  • Naresh Bumma

  • Dominique Chauveau

  • Meletios A Dimopoulos

  • NamPhuong Tran

  • Xiang Qin

  • Sandra Y. Vasey

  • Brenda Tromp

  • Brendan M. Weiss

  • Jessica Vermeulen

  • Giampaolo Merlini

Medical Centers

  • Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece

  • Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Department of Molecular Medicine, University of Pavia,Pavia,Italy

  • Department of Hematology, UMC Utrecht Cancer Center, Utrecht, Netherlands

  • Kings College London, London, United Kingdom

  • Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France

  • Cancer Center, Boston University School of Medicine, Boston, MA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The Victorian and Tasmanian Amyloidosis Service, Department of Haematology, Monash University Easter Health Clinical School, Melbourne, VIC, Australia

  • Dept of Pathology, Department of Pathology, Princess Alexandra Hospital, Brisbane, Australia

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

  • Peking University People’s Hospital, National Clinical Research Center for Hematologic Disease, Collaborative Innovation Center of Hematology, Beijing, China

  • Medical Department V, Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany

  • Department of Radiation Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel

  • Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Cebeci Yerleskesi Dikimevi, Ankara, Turkey

  • Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA

  • Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

  • Sao Germano Clinic, Sao Paulo, Brazil

  • St Marys Medical Center, San Francisco, CA

  • Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • CHU Toulouse - Hopital Rangueil-Purpan, Toulouse, France

  • Athens School of Medicine, Athens, Greece

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, Leiden, Netherlands

  • Janssen Research & Development, Leiden, Netherlands

  • Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

Locations

  • United States

  • Greece

  • Italy

  • Netherlands

  • United Kingdom

  • France

  • Australia

  • Canada

  • China

  • Germany

  • Israel

  • Japan

  • Republic of South Korea

  • Spain

  • Turkey

  • Brazil

Companies

  • JB Medical Ltd.

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • End stage renal disease

  • Multiple Myeloma

  • AL Amyloidosis

  • Renal disease

  • Amyloid disease

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Hyaluronidase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Bortezomib

  • Lanthanum carbonate

  • Sparsentan

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT03201965

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved